Therefore, in this study, we explored the molecular mechanism by which RCE inhibits inflammation in COPD, with a focus on the IL-1β/Cox-2 signaling pathway, via animal experiments in vivo and cells assay in vitro, which provides strong evidence for its clinical use in the treatment of COPD. Here, PTGS2 is linked to chronic obstructive pulmonary disease.